uniQure (NASDAQ:QURE) Trading Down 4.2% - Time to Sell?

uniQure (NASDAQ:QURE - Get Free Report)'s share price was down 4.2% during trading on Thursday . The company traded as low as $12.99 and last traded at $13.08. Approximately 453,645 shares were traded during mid-day trading, a decline of 55% from the average daily volume of 1,015,442 shares. The stock had previously closed at $13.65.

Analyst Ratings Changes

A number of research firms have weighed in on QURE. Guggenheim reissued a "buy" rating on shares of uniQure in a research report on Wednesday, December 11th. Stifel Nicolaus lifted their target price on shares of uniQure from $12.00 to $32.00 and gave the stock a "buy" rating in a research note on Monday, December 16th. Royal Bank of Canada restated an "outperform" rating and issued a $24.00 target price on shares of uniQure in a report on Tuesday, January 21st. Wells Fargo & Company decreased their price target on uniQure from $35.00 to $30.00 and set an "equal weight" rating for the company in a report on Friday, February 28th. Finally, The Goldman Sachs Group boosted their price objective on uniQure from $9.00 to $20.00 and gave the company a "neutral" rating in a research note on Thursday, December 12th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, uniQure currently has an average rating of "Moderate Buy" and a consensus price target of $38.89.

uniQure Stock Performance

The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. The company has a fifty day moving average price of $13.77 and a 200 day moving average price of $10.83. The stock has a market cap of $573.22 million, a P/E ratio of -2.14 and a beta of 0.36.

Insider Buying and Selling

In other uniQure news, CFO Christian Klemt sold 10,438 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total value of $107,407.02. Following the completion of the sale, the chief financial officer now owns 217,730 shares in the company, valued at approximately $2,240,441.70. This trade represents a 4.57 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Matthew C. Kapusta sold 28,341 shares of uniQure stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total transaction of $291,628.89. Following the transaction, the chief executive officer now directly owns 651,454 shares in the company, valued at approximately $6,703,461.66. This represents a 4.17 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 90,830 shares of company stock worth $961,401 in the last quarter. Insiders own 4.74% of the company's stock.

Institutional Investors Weigh In On uniQure

Several large investors have recently added to or reduced their stakes in QURE. Point72 Asset Management L.P. raised its stake in shares of uniQure by 336.1% during the 3rd quarter. Point72 Asset Management L.P. now owns 976,893 shares of the biotechnology company's stock valued at $4,816,000 after purchasing an additional 752,889 shares during the period. Walleye Capital LLC bought a new position in uniQure in the third quarter valued at $444,000. FMR LLC raised its position in uniQure by 8,056.6% during the third quarter. FMR LLC now owns 350,572 shares of the biotechnology company's stock valued at $1,728,000 after purchasing an additional 346,274 shares in the last quarter. Sanders Morris Harris LLC boosted its holdings in shares of uniQure by 50.0% in the 4th quarter. Sanders Morris Harris LLC now owns 102,104 shares of the biotechnology company's stock worth $1,803,000 after purchasing an additional 34,034 shares in the last quarter. Finally, Franklin Resources Inc. purchased a new position in shares of uniQure during the 3rd quarter valued at about $7,360,000. Hedge funds and other institutional investors own 78.83% of the company's stock.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.